New drug IOA-244 aims to boost immune system against advanced cancers
NCT ID NCT04328844
First seen Apr 07, 2026 · Last updated Apr 30, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers, including solid tumors, lymphoma, and melanoma. The main goal is to check if the drug is safe and tolerable, and to see if it can boost the body's immune response against tumors, either alone or with other cancer treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
Humanitas Research Hospital
Rozzano, Milan, 20089, Italy
-
Medical Oncology and Immunotherapy Unit, University Hospital of Siena
Siena, 53100, Italy
Conditions
Explore the condition pages connected to this study.